[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68 (6) :394-424.
|
[2] CHEN WQ, SUN KX, ZHENG RS, et al. Report of cancer incidence and mortality in different areas of China, 2014[J]. China Cancer, 2018, 27 (1) :1-14. (in Chinese) 陈万青, 孙可欣, 郑荣寿, 等. 2014年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤, 2018, 27 (1) :1-14.
|
[3] FRAMPAS E, DAVID A, REGENET N, et al. Pancreatic carcinoma:Key-points from diagnosis to treatment[J]. Diagn Interv Imaging, 2016, 97 (12) :1207-1223.
|
[4] YANG YM, LI JS. Current status and progress of comprehensive treatment for locally advanced pancreatic cancer[J].Chin J Dig Surg, 2017, 16 (10) :979-982. (in Chinese) 杨尹默, 李佶松.局部进展期胰腺癌综合治疗的现状与进展[J].中华消化外科杂志, 2017, 16 (10) :979-982.
|
[5] de LUCA R, BLASI L, ALU M, et al. Clinical efficacy of nabpaclitaxel in patients with metastatic pancreatic cancer[J].Drug Des Devel Ther, 2018, 12:1769-1775.
|
[6] TAHARA J, SHIMIZU K, OTSUKA N, et al. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer[J]. Cancer Chemother Pharmacol, 2018, 82 (2) :245-250.
|
[7] KANG J, HWANG I, YOO C, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer:Retrospective analysis[J]. Invest New Drugs, 2018, 36 (4) :732-741.
|
[8] CARTWRIGHT TH, PARISI M, ESPIRITO JL, et al. Clinical outcomes with first-line chemotherapy in a large retrospective study of patients with metastatic pancreatic cancer treated in a US community oncology setting[J]. Drugs Real World Outcomes, 2018, 5 (3) :149-159.
|
[9] KIM S, SIGNOROVITCH JE, YANG H, et al. Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer:A retrospective nationwide chart review in the United States[J]. Adv Ther, 2018, 35 (10) :1564-1577.
|
[10] MURANAKA T, KUWATANI M, KOMATSU Y, et al. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer[J]. J Gastrointest Oncol, 2017, 8 (3) :566-571.
|
[11] WANG Y, CAMATEROS P, CHEUNG WY. A real-world comparison of FOLFIRINOX, gemcitabine plus nab-paclitaxel, and gemcitabine in advanced pancreatic cancers[J]. J Gastrointest Cancer, 2019, 50 (1) :62-68.
|
[12] BRAITEH F, PATEL MB, PARISI M, et al. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting[J]. Cancer Manag Res, 2017, 9:141-148.
|
[13] CHAPMAN BC, GLEISNER A, RIGG D, et al. Perioperative and Survival outcomes following neoadjuvant FOLFIRINOX versus gemcitabine abraxane in patients with pancreatic adenocarcinoma[J]. Med Oncol, 2018, 19 (2) :75-85.
|
[14] DHIR M, ZENATI MS, HAMAD A, et al. FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma[J]. Ann Surg Oncol, 2018, 25 (7) :1896-1903.
|
[15] HEGEWISCH-BECKER S, ALDAOUD A, WOLF T, et al. Results from the prospective German TPK clinical cohort study:Treatment algorithms and survival of 1, 174 patients with locally advanced, inoperable or metastatic pancreatic ductal adenocarcinoma[J]. Int J Cancer, 2019, 144 (5) :981-990.
|
[16] von HOFF DD, ERVIN T, ARENA FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369 (18) :1691-1703.
|